Rapamycin inhibits proliferative signals mediated by CD40 ligand
| . | Medium . | CD40LH . | CD40LH + rapamycin . | CD40LH + IL-2 + IL-10 . | CD40LH + IL-2 + IL-10 + rapamycin . |
|---|---|---|---|---|---|
| 1 | 540 ± 105 | 14 085 ± 1134 | 596 ± 30 | 13 336 ± 3064 | 480 ± 46 |
| 2 | 410 ± 80 | 558 ± 133 | 540 ± 80 | 10 305 ± 1007 | 2610 ± 341 |
| 3 | 353 ± 104 | 397 ± 38 | 410 ± 112 | 21 984 ± 6402 | 374 ± 67 |
| . | Medium . | CD40LH . | CD40LH + rapamycin . | CD40LH + IL-2 + IL-10 . | CD40LH + IL-2 + IL-10 + rapamycin . |
|---|---|---|---|---|---|
| 1 | 540 ± 105 | 14 085 ± 1134 | 596 ± 30 | 13 336 ± 3064 | 480 ± 46 |
| 2 | 410 ± 80 | 558 ± 133 | 540 ± 80 | 10 305 ± 1007 | 2610 ± 341 |
| 3 | 353 ± 104 | 397 ± 38 | 410 ± 112 | 21 984 ± 6402 | 374 ± 67 |
105 purified B-CLL cells were cultured in medium alone or in the presence of 104 irradiated HeLa cells stably expressing the CD40 ligand (CD40LH), IL-2 (100 U/mL), IL-10 (1 ng/mL), or rapamycin (50 ng/mL) as indicated. After 120 hours, thymidine was added for an additional 8 hours of culture, and thymidine incorporation was assessed as described in “Patients, materials, and methods.”